Observational Study
Copyright ©The Author(s) 2024.
World J Hepatol. Feb 27, 2024; 16(2): 241-250
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.241
Table 1 Demonthsgraphic and clinical characteristics of the study population at baseline
Variables
Data
Gender
Men, n (%)21 (46.7)
Female, n (%)24 (53.3)
Age (yr)47.62 ± 11.16
Etiology
HBV, n (%)37 (74.0)
HCV, n (%)2 (4.0)
AIH, n (%)4 (8.0)
Unexplained cirrhosis, n (%)2 (4.0)
WBC (109/L)2.21 ± 1.18
RBC (1012/L)3.68 ± 0.78
PLT (109/L)44.09 ± 28.54
AST (U/L)35.18 ± 14.82
ALT (U/L)26.89 ± 14.30
TBIL (μmol/L)26.77 ± 15.97
ALB (g/L)38.81 ± 4.16
INR1.30 ± 0.19
PT (s)14.23 ± 1.94
PTA (%)68.71 ± 13.45
D-D2 (mg/L)0.56 ± 1.03
MELD10.76 ± 3.30
PVD (mm)13.66 ± 2.49
PV (cm/s)19.87 ± 5.88
SVD (mm)10.35 ± 2.61
Ascites, n (%)19 (42.2)
Child-Pugh grade
A, n (%)32 (71.1)
B, n (%)13 (28.9)
C, n (%)0 (0.0)
Operation ways1.30 ± 0.19
Open splenectomy, n (%)35 (78.8)
Laparoscopic splenectomy, n (%)10 (21.2)
Spleen volume (cm3)2349.28 (531.12-13080.00)
Table 2 Independent risk factors of portal vein thrombosis formation in patients with liver cirrhosis after splenectomy
Variable
PVT
Non-PVT
P value
OR
95%CI
Postoperative 1-month
Age45.72 ± 7.8448.89 ± 12.91
PVD14.79 ± 2.0812.60 ± 2.380.0282.1941.090-4.415
MELD > 1012 (70.6)8 (32.0)0.01376.2152.534-2287.318
PLT47.00 ± 41.9642.15 ± 14.78
Postoperative 3-months
Age44.71 ± 7.9644.71 ± 7.96
PT14.69 ± 1.9414.69 ± 1.94
PVD14.71 ± 2.1614.71 ± 2.160.031.71.052-2.746
Meld > 1012 (70.6)8 (32.0)0.02812.3921.318-116.548
PLT47.57 ± 38.8041.04 ± 15.11
Postoperative 12-months
Age44.64 ± 7.7750.4 ± 13.19
PVD14.60 ± 2.1312.64 ± 2.470.0371.7761.036-3.046
MELD > 1014 (63.6)6 (26.1)0.01523.9251.875-305.323
PLT46.55 ± 38.1741.74 ± 15.05